QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company dedicated to transforming breast health management through innovative, radiation-free imaging technology, today announced a collaboration with Olea Medical, a renowned provider of advanced medical imaging software, recognized for its clinically validated quantitative analytics and multimodality expertise across magnetic resonance (MR), computed tomography (CT) and ultrasound (US) imaging.

This collaboration enhances QT Imaging’s Cloud SaaS Platform by integrating Olea Medical’s advanced visualization, quantitative analytics and AI-ready imaging technologies to support clinical interpretation, research workflows, and quantitative imaging analysis. The Olea collaboration builds on QT Imaging’s existing cloud infrastructure, to be delivered through InteleShare platform, which provides the enterprise PACS and cloud backbone for QT Imaging’s clinical and research deployments.

Together, these capabilities strengthen QT Imaging’s end-to-end imaging ecosystem, enabling secure cloud-based delivery of QT Imaging Breast Acoustic CT™ studies with high-performance visualization, advanced quantitative analysis, and multimodality integration.

Under the collaboration:

• QT imaging data will be enabled for relevant clinical interpretation within QT Imaging’s infrastructure, incorporating Olea Medical’s validated visualization and analytics technologies.
• The combined solution supports a scalable multimodality breast imaging approach, integrating mammography, digital breast tomosynthesis (DBT), ultrasound, MR imaging and QT Imaging studies across the breast care pathway.
• Advanced quantitative analytics, segmentation and volumetric analysis, will support improved lesion characterization, diagnostic confidence, and clinical efficiency.
• Secure, network-enabled access enables multi-institutional collaboration, centralized research workflows, and standardized clinical trial support.

The collaboration aligns with QT Imaging’s roadmap to expand adoption of its Breast Acoustic CT™ technology while supporting future AI- and machine learning-driven analytics, delivered through its cloud infrastructure.

As part of the collaboration, QT Imaging will distribute the QT Imaging Olea Vision software, a highly customizable 3D and 4D DICOM viewer with user-defined hanging protocols offering functionalities such as intuitive navigation across DICOM series, advanced 3D data loading and visualization, and image manipulation. The software also includes subtraction tools to support enhanced diagnostic assessment.

“Our collaboration with Olea Medical strengthens the clinical visualization and analytical capabilities of QT Imaging’s cloud platform,” said Dr. Raluca Dinu, Chief Executive Officer of QT Imaging. “Together with the enterprise delivery infrastructure we are putting in place, this collaboration supports our mission to deliver advanced, quantitative breast imaging at scale for both research and clinical care.”

“We are pleased to collaborate with QT Imaging to bring our advanced visualization and quantitative imaging expertise into next-generation breast imaging,” said Dr. Faycal Djeridane, Founder and CEO of Olea Medical. “This collaboration reflects a shared commitment to clinically meaningful innovation, multimodality integration and quantitative imaging.”

This collaboration further reinforces QT Imaging’s strategy to deliver a unified, cloud-enabled imaging platform that bridges novel acoustic imaging, traditional radiology modalities, and advanced quantitative analytics through a trusted and clinically established software partner.

About Olea Medical

Olea Medical, a Canon Medical Systems Corporation company, is a medical imaging software provider specializing in advanced MR, CT, and US imaging post-processing solutions. Based in La Ciotat, France, the company has established its credibility through the clinical translation of cutting-edge technologies and long-standing partnerships with leading academic and clinical institutions worldwide.

Olea Medical’s solutions combine artificial intelligence-assisted technologies with proprietary Bayesian algorithms and advanced optimization methods applied to medical imaging. As a result, Olea Medical is a recognized player in standardized, vendor-neutral, advanced quantitative and qualitative imaging, supporting both morphological and functional analysis across MR, CT, and US imaging.

By bringing complex mathematical models into routine clinical practice, Olea Medical enables easy access to accurate, robust imaging biomarkers, supporting enhanced diagnostic confidence, longitudinal analysis, and response-to-treatment assessment across a broad range of clinical applications.

For more information, please visit http://www.olea-medical.com.

About QT Imaging Holdings, Inc.

QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the Company’s website at www.qtimaging.com.

Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as “will,” and “expect,” or the negative thereof or comparable terminology, and include (without limitation) statements regarding the collaboration between QT Imaging and Olea Medical, the integration of Olea Medical’s technology with QT Imaging’s Cloud SaaS Platform and the distribution of the QT Imaging Olea Vision software, sales of Olea Vision and the compatibility of the technology with the QTI Breast Acoustic CT scanner, the presentation and performance of the QTI Breast Acoustic CT imaging technology, plans for QT Imaging, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QTI Breast Acoustic CT scanner, clinical studies, the ability of QT Imaging to sell and deploy the QTI Breast Acoustic CT scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and “bring to market” plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading “Risk Factors” and in other sections of QT Imaging Holding’s filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260127325750/en/